GlassScriptPhysician profile
Brandon W Lee
NPI 1801042007
$13,106.06
in general payments reported to CMS, 2019-2025
33 companies · $3,051 in 2025
The $3,051 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $779 · 2021: $1,255 · 2022: $2,317 · 2023: $2,357 · 2024: $1,607 · 2025: $3,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,998 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,997.97 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,343.84 | 2019-2025 | Clareon, Rocklatan, Unity |
| Abbvie INC. | $998.07 | 2022-2025 | |
| Glaukos Corporation | $861.57 | 2021-2025 | Idosetr, Istent Infinite, Photrexa Viscous and Photrexa |
| Sight Sciences, INC. | $859.59 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $822.67 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $744.30 | 2019-2023 | Tecnis Iol |
| Genentech USA, INC. | $617.49 | 2022-2025 | Vabysmo |
| Horizon Therapeutics Plc | $533.94 | 2022-2023 | Tepezza |
| Amgen INC. | $508.88 | 2024-2025 | Tepezza, Pavblu |
| Bausch & Lomb Americas INC. | $449.48 | 2022-2025 | Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $428.49 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $410.49 | 2019-2025 | Cequa |
| Regeneron Healthcare Solutions, INC. | $399.69 | 2019-2025 | Eylea Hd |
| Dompe US, INC. | $362.28 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $323.71 | 2024-2025 | Xdemvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $229.23 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $211.81 | 2019-2021 | |
| Shire North American Group INC | $168.67 | 2019 | |
| Oyster Point Pharma, INC. | $167.35 | 2022-2025 | Tyrvaya, Ryzumvi |
| New World Medical,INC. | $144.98 | 2019 | |
| Allergan, INC. | $84.74 | 2020-2022 | |
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Eyevance Pharmaceuticals LLC | $49.80 | 2020-2021 | |
| Abbott Laboratories | $47.84 | 2020 | |
| Harrow Eye, LLC | $44.31 | 2025 | Tobradex St, Iheezo, Natacyn |
| Optos, INC. | $38.26 | 2019 | |
| Rxsight INC | $36.35 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Galderma Laboratories, L.P. | $27.14 | 2021 | |
| Mallinckrodt Enterprises LLC | $26.14 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.84 | 2021 | |
| Beaver-Visitec International, INC. | $21.66 | 2025 | |
| Rayner Intraocular Lenses Limited | $21.62 | 2022 | |
| Coopervision INC. | $15.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.